This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|May 6, 2020
Augury Adds Machine Health Monitoring Features
Author(s)BioPharm International Editors
Remote, machine health monitoring services reduce the need for on-site visits.
Advertisement
Augury introduced new features and services for machine health monitoring in industrial facilities, the company announced in a May 6, 2020 press release. The company added guided self-installation capabilities so customers can implement machine health monitoring in new facilities even when access may be restricted. This feature allows customers to install Augury monitoring components themselves, guided remotely by Augury personnel.
“Our customers are telling us that machine health and remote collaboration matter more than ever to them, and they want to expand their deployment of digital solutions in these challenging times,” said Saar Yoskovitz, CEO of Augury, in the press release.
New features include customized notifications and Threads Tagging, which works similarly to other collaboration tools by allowing users to notify team members or subject matter experts if they want their attention on a certain question or issue. The conversations are preserved in the platform to help users in future similar situations and as a way to share best practices across the entire team, the company said in the press release.
The Early Insights feature uses artificial intelligence to deliver alerts more quickly and provide richer context around the alert to help solve problems more quickly. According to the press release, the feature helps reduce risk for machines that are degrading quickly.
Automated connectivity alerts, extended battery life, and power over ethernet for monitoring components eliminates gaps in monitoring while reducing the need for on-site visits by employees and contractors.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5